Delphi advisor to Mendus in connection with directed issue and rights issue

Delphi has assisted Mendus AB (publ) in connection with a directed issue and a fully secured rights issue of units amounting to a total of approximately SEK 317 million.

In connection with the capital raising, Mendus has entered into a strategic manufacturing alliance with NorthX Biologics, a biologics contract manufacturing organization, offering services and support in the development and manufacturing of biologics used in vaccines, gene therapy and other advanced therapies, to support the manufacturing of Mendus’ lead program vididencel.

Mendus is a biopharmaceutical company focused changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients. Mendus is listed on Nasdaq Stockholm.

Delphi’s team consisted of Mats Dahlberg, Jenny Lindén and Tove Rodlert.